Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction
Open Access
- 29 January 2005
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 144 (2) , 202-211
- https://doi.org/10.1038/sj.bjp.0705867
Abstract
M Adenosine 5′‐triphosphate (ATP) is known to augment cardiac contractile activity and cause an increase in intracellular Ca2+ concentration ([Ca2+]i) in isolated cardiomyocytes. However, no information regarding the ATP‐mediated signal transduction in the myocardium in congestive heart failure (CHF) is available. CHF due to myocardial infarction (MI) in rats was induced by the occlusion of the left coronary artery for 8 weeks. The positive inotropy due to ATP was depressed in failing hearts. Treatment of 3 weeks infarcted animals with imidapril (1 mg kg−1 day−1) for a period of 5 weeks improved the left ventricle function and decreased the attenuation of inotropic response to ATP. ATP‐induced increase in [Ca2+]i was significantly depressed in cardiomyocytes isolated from the failing heart and this change was partially attenuated by imidapril treatment. However, the binding characteristics of 35S‐labeled adenosine 5′‐(γ‐thio) triphosphate in sarcolemma isolated from the failing heart remained unaltered. ATP‐induced increase in [Ca2+]i was depressed by verapamil and cibacron blue in both control and failing heart cardiomyocytes; however, the ATP response in the failing hearts, unlike the control preparations, was not decreased by ryanodine. This insensitivity to ryanodine was attenuated by imidapril treatment. Treatment of infarcted rats with enalapril and losartan produced effects similar to imidapril. These findings indicate that the positive inotropic response to ATP and ATP‐induced increase in [Ca2+]i in cardiomyocytes are impaired in heart failure. Furthermore, blockade of renin angiotensin system prevented the impairment of the ATP‐mediated inotropic and [Ca2+]i responses in the failing heart. British Journal of Pharmacology (2005) 144, 202–211. doi:10.1038/sj.bjp.0705867Keywords
This publication has 70 references indexed in Scilit:
- Improving clinical outcomes with drug treatment in heart failure: what have trials taught?The American Journal of Cardiology, 2003
- L-Type Ca 2+ Channel Density and Regulation Are Altered in Failing Human Ventricular Myocytes and Recover After Support With Mechanical Assist DevicesCirculation Research, 2002
- Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy?Cardiovascular Research, 2002
- Captopril Treatment Improves the Sarcoplasmic Reticular Ca2+Transport in Heart Failure Due to Myocardial InfarctionJournal of Molecular and Cellular Cardiology, 1999
- Mechanisms of Cardiomyocyte Dysfunction in Heart Failure Following Myocardial Infarction in RatsJournal of Molecular and Cellular Cardiology, 1998
- Electrocardiographic Changes and Mortality Due to Myocardial Infarction in Rats With or Without Imidapril TreatmentJournal of Cardiovascular Pharmacology and Therapeutics, 1998
- Effects of Trandolapril on Cardiac Angiotensin I Converting Enzyme Activity in Rats with Chronic Heart Failure Following Myocardial Infarction.Japanese Heart Journal, 1995
- Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension, 1994
- Extracellular ATP induces Ca2+ transients in cardiac myocytes which are potentiated by norepinephrineFEBS Letters, 1987
- Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.Circulation, 1982